QQQ   354.95 (+0.84%)
AAPL   180.63 (+0.30%)
MSFT   336.37 (+1.14%)
META   273.60 (+0.36%)
GOOGL   125.06 (+1.08%)
AMZN   124.74 (+1.60%)
TSLA   215.93 (+4.05%)
NVDA   393.19 (-1.13%)
NIO   7.63 (+1.19%)
BABA   84.57 (+1.89%)
AMD   118.22 (-1.05%)
T   15.17 (-4.05%)
F   12.43 (+2.64%)
MU   69.18 (+0.13%)
CGC   0.82 (-1.77%)
GE   106.53 (+1.78%)
DIS   91.01 (+2.73%)
AMC   4.57 (+0.44%)
PFE   38.50 (+1.26%)
PYPL   64.06 (+1.60%)
NFLX   402.37 (-0.19%)
QQQ   354.95 (+0.84%)
AAPL   180.63 (+0.30%)
MSFT   336.37 (+1.14%)
META   273.60 (+0.36%)
GOOGL   125.06 (+1.08%)
AMZN   124.74 (+1.60%)
TSLA   215.93 (+4.05%)
NVDA   393.19 (-1.13%)
NIO   7.63 (+1.19%)
BABA   84.57 (+1.89%)
AMD   118.22 (-1.05%)
T   15.17 (-4.05%)
F   12.43 (+2.64%)
MU   69.18 (+0.13%)
CGC   0.82 (-1.77%)
GE   106.53 (+1.78%)
DIS   91.01 (+2.73%)
AMC   4.57 (+0.44%)
PFE   38.50 (+1.26%)
PYPL   64.06 (+1.60%)
NFLX   402.37 (-0.19%)
QQQ   354.95 (+0.84%)
AAPL   180.63 (+0.30%)
MSFT   336.37 (+1.14%)
META   273.60 (+0.36%)
GOOGL   125.06 (+1.08%)
AMZN   124.74 (+1.60%)
TSLA   215.93 (+4.05%)
NVDA   393.19 (-1.13%)
NIO   7.63 (+1.19%)
BABA   84.57 (+1.89%)
AMD   118.22 (-1.05%)
T   15.17 (-4.05%)
F   12.43 (+2.64%)
MU   69.18 (+0.13%)
CGC   0.82 (-1.77%)
GE   106.53 (+1.78%)
DIS   91.01 (+2.73%)
AMC   4.57 (+0.44%)
PFE   38.50 (+1.26%)
PYPL   64.06 (+1.60%)
NFLX   402.37 (-0.19%)
QQQ   354.95 (+0.84%)
AAPL   180.63 (+0.30%)
MSFT   336.37 (+1.14%)
META   273.60 (+0.36%)
GOOGL   125.06 (+1.08%)
AMZN   124.74 (+1.60%)
TSLA   215.93 (+4.05%)
NVDA   393.19 (-1.13%)
NIO   7.63 (+1.19%)
BABA   84.57 (+1.89%)
AMD   118.22 (-1.05%)
T   15.17 (-4.05%)
F   12.43 (+2.64%)
MU   69.18 (+0.13%)
CGC   0.82 (-1.77%)
GE   106.53 (+1.78%)
DIS   91.01 (+2.73%)
AMC   4.57 (+0.44%)
PFE   38.50 (+1.26%)
PYPL   64.06 (+1.60%)
NFLX   402.37 (-0.19%)
NASDAQ:CCCC

C4 Therapeutics (CCCC) Stock Forecast, Price & News

$3.44
+0.08 (+2.38%)
(As of 02:49 PM ET)
Compare
Today's Range
$3.31
$3.46
50-Day Range
$2.96
$3.54
52-Week Range
$2.85
$13.23
Volume
459,876 shs
Average Volume
560,024 shs
Market Capitalization
$168.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.86

C4 Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
184.9% Upside
$9.86 Price Target
Short Interest
Bearish
7.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.25mentions of C4 Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.91) to ($2.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

788th out of 983 stocks

Biological Products, Except Diagnostic Industry

130th out of 164 stocks


CCCC stock logo

About C4 Therapeutics (NASDAQ:CCCC) Stock

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Receive CCCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CCCC Stock News Headlines

The Latest Analyst Ratings for C4 Therapeutics
Is Graphite the New Lithium?
Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.
C4 Therapeutics (NASDAQ:CCCC) PT Lowered to $10.00
Is Graphite the New Lithium?
Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.
Expert Ratings for C4 Therapeutics
C4 Therapeutics (CCCC) Receives a Buy from SVB Securities
Recap: C4 Therapeutics Q1 Earnings
Brokerages Set C4 Therapeutics, Inc. (NASDAQ:CCCC) PT at $14.33
See More Headlines

CCCC Price History

CCCC Company Calendar

Last Earnings
11/10/2021
Today
6/02/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CCCC
Fax
N/A
Employees
121
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.86
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+193.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
7 Analysts

Profitability

Net Income
$-128,180,000.00
Net Margins
-482.83%
Pretax Margin
-482.83%

Debt

Sales & Book Value

Annual Sales
$31.10 million
Book Value
$5.35 per share

Miscellaneous

Free Float
42,112,000
Market Cap
$164.84 million
Optionable
Not Optionable
Beta
2.09

Key Executives

  • Mr. Andrew J. Hirsch (Age 52)
    CEO, Pres & Director
    Comp: $952.2k
  • Dr. Kenneth C. Anderson M.D. (Age 72)
    Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board
    Comp: $35k
  • Ms. Lauren A. White
    Chief Financial Officer
  • Dr. Stewart FisherDr. Stewart Fisher (Age 56)
    Chief Scientific Officer
    Comp: $694.7k
  • Ms. Jolie M. Siegel J.D. (Age 46)
    Chief Legal Officer
    Comp: $610.4k
  • Dr. Adam S. Crystal M.D. (Age 46)
    Ph.D., Chief Medical Officer
    Comp: $701.7k
  • Dr. Nathanael S. Gray Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Ms. Kendra Adams
    Sr. VP of Communications & Investor Relations
  • Kristina Zambouras
    Director of HR
  • Ms. Kelly Schick
    Chief People Officer













CCCC Stock - Frequently Asked Questions

Should I buy or sell C4 Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last year. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CCCC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CCCC, but not buy additional shares or sell existing shares.
View CCCC analyst ratings
or view top-rated stocks.

What is C4 Therapeutics' stock price forecast for 2023?

7 Wall Street research analysts have issued 1 year price targets for C4 Therapeutics' stock. Their CCCC share price forecasts range from $5.00 to $25.00. On average, they anticipate the company's share price to reach $9.86 in the next year. This suggests a possible upside of 193.4% from the stock's current price.
View analysts price targets for CCCC
or view top-rated stocks among Wall Street analysts.

How have CCCC shares performed in 2023?

C4 Therapeutics' stock was trading at $5.90 at the beginning of the year. Since then, CCCC shares have decreased by 43.1% and is now trading at $3.36.
View the best growth stocks for 2023 here
.

When is C4 Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our CCCC earnings forecast
.

How were C4 Therapeutics' earnings last quarter?

C4 Therapeutics, Inc. (NASDAQ:CCCC) released its earnings results on Wednesday, November, 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.06. The firm had revenue of $8.50 million for the quarter, compared to the consensus estimate of $7.28 million. C4 Therapeutics had a negative trailing twelve-month return on equity of 43.26% and a negative net margin of 482.83%.

What ETFs hold C4 Therapeutics' stock?

ETFs with the largest weight of C4 Therapeutics (NASDAQ:CCCC) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).Harbor Disruptive Innovation ETF (INNO).

When did C4 Therapeutics IPO?

(CCCC) raised $150 million in an initial public offering (IPO) on Friday, October 2nd 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO.

What is C4 Therapeutics' stock symbol?

C4 Therapeutics trades on the NASDAQ under the ticker symbol "CCCC."

Who are C4 Therapeutics' major shareholders?

C4 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (13.01%), Wasatch Advisors LP (11.65%), BlackRock Inc. (7.53%), Price T Rowe Associates Inc. MD (5.86%), Geode Capital Management LLC (1.71%) and State Street Corp (1.58%). Insiders that own company stock include Adam Crystal, Andrew Hirsch, Elena Prokupets, Jolie Siegel, Malcolm Salter, Marc A Cohen, Stewart Fisher, Utpal Koppikar and William Mckee.
View institutional ownership trends
.

How do I buy shares of C4 Therapeutics?

Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is C4 Therapeutics' stock price today?

One share of CCCC stock can currently be purchased for approximately $3.36.

How much money does C4 Therapeutics make?

C4 Therapeutics (NASDAQ:CCCC) has a market capitalization of $164.84 million and generates $31.10 million in revenue each year. The company earns $-128,180,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis.

How many employees does C4 Therapeutics have?

The company employs 121 workers across the globe.

How can I contact C4 Therapeutics?

The official website for the company is www.c4therapeutics.com. The company can be reached via phone at 617-231-0700 or via email at jane.urheim@sternir.com.

This page (NASDAQ:CCCC) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -